ASX:CUV
ASX:CUVBiotechs

Clinuvel Pharmaceuticals (ASX:CUV): Valuation Insights After SEC Review Delay and Share Price Dip

Clinuvel Pharmaceuticals (ASX:CUV) shared that the ongoing U.S. Federal government shutdown is expected to slow the review and approval of its SEC filings. The company’s share price slipped following news of the delay. See our latest analysis for Clinuvel Pharmaceuticals. Clinuvel’s share price has steadily softened this year, with a 30-day share price return of -10.26% hinting at fading momentum. Ongoing SEC-related delays are adding to the pressure. The bigger picture shows a one-year total...
ASX:CSL
ASX:CSLBiotechs

Why CSL (ASX:CSL) Is Down 17.0% After Board Changes and Lowered Revenue Growth Guidance

At its October 2025 Annual General Meeting, CSL Limited announced the retirement of Dr. Megan Clark and Ms. Marie McDonald from the Board, while appointing Mr. Costa Saroukis and Mr. Gordon Naylor as new Directors effective December 1, 2025. The leadership transition coincided with lowered revenue growth guidance for financial year 2026, signaling a period of recalibration in CSL's strategy as it aligns board expertise with shifts in the business outlook. We'll explore how CSL's revised...
ASX:BBL
ASX:BBLEntertainment

3 Promising ASX Penny Stocks With Over A$90M Market Cap

As the Australian market steadies ahead of a significant Reserve Bank rate decision, investors are navigating a landscape marked by stable indices and cautious optimism. Penny stocks, often seen as relics of past market eras, continue to offer intriguing opportunities for growth through smaller or newer companies. With strong financial health and solid fundamentals, these stocks can provide a unique mix of affordability and potential returns.
ASX:WBC
ASX:WBCBanks

Westpac (ASX:WBC) Margin Decline Reinforces Concerns Over Premium Valuation

Westpac Banking (ASX:WBC) reported earnings growth of 3.93% per year, with revenue tracking slightly behind at 3.6% per year. The company’s current net profit margin is 31.5%, reflecting a modest decline from last year's 33.2%. Over the last five years, Westpac delivered a solid 12.4% annualized earnings growth, and its earnings quality remains high, although growth forecasts suggest the bank will lag the broader Australian market. See our full analysis for Westpac Banking. Next up, we’ll see...